---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-282059"
form_type: "8-K"
ticker: "IMA"
cik: "0001835579"
company_name: "ImageneBio, Inc."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T23:46:23.992346+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Ikena Oncology reports initial IK-175 clinical data: 20% ORR in combination with nivolumab in urothelial carcinoma

## Summary
- IK-175 combo with nivolumab: 20% ORR, 40% DCR in heavily pretreated urothelial carcinoma patients who progressed on checkpoint inhibitors.
- Monotherapy: 10% ORR, 20% DCR; one confirmed partial response with duration of response 14.9 months and ongoing.
- Dose escalation in solid tumors: prolonged stable disease up to >19 months; MTD not reached; 1200mg selected as expansion dose.
- Well tolerated with low-grade rash, nausea (monotherapy) and fatigue, dysgeusia (combo); only 2 serious adverse events.
- Program in collaboration with Bristol Myers Squibb; opt-in decision eligible through early 2024.

## SEC filing metadata
- accession: 0001193125-22-282059
- form_type: 8-K
- ticker: IMA
- cik: 0001835579
- company_name: ImageneBio, Inc.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835579/000119312522282059/0001193125-22-282059-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835579/000119312522282059/d410137d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-282059
- JSON: https://secwatch.observer/filing/0001193125-22-282059.json
- Plain text: https://secwatch.observer/filing/0001193125-22-282059.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.